BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Applied Data Research Release: Branded Cellular Therapies Creating a ‘Toolbox’ of Options for Cardiologists


3/26/2008 1:16:51 PM

(Nashua, NH) – The field of cardiology has struggled to address the problems of patients with compromised or diminished cardiovascular function – a population that represents the largest single treatable patient segment in healthcare. New drugs and innovative devices have improved patient quality-of-life, but have done little to decrease mortality and morbidity. Transplantation remains a high-risk procedure with chronic supply and histocompatibility issues. Synthetic materials as tissue replacements suffer from biocompatibility problems and are prone to thrombosis.

For more than a decade, research teams have explored technologies with the capacity to regenerate damaged heart tissue as a way to restore heart function with little progress. But in the last three years – armed with enabling technologies that include advances in stem cell collection, control and proliferation, recombinant protein manufacturing, and tissue engineering – a number of companies have achieved outcomes in the clinical that demonstrate restored cardiac function in patients with diseased hearts and pave the way for a new generation of treatment tools in cardiac medicine.

More than two dozen companies are currently shepherding cell-based cardiac therapy products through various stages of development and clinical validation. Several have received FDA Orphan Status or Fast Track designation. As milestones are achieved, the interest of major pharma and biotech companies is increasing, setting the stage for a spike in alliance and investment activity that will help propel the segment toward successful product and therapy commercialization.

These developments are examined in a new and comprehensive report – Branded Cellular Therapies in Cardiac Medicine: Platforms, Players and Prospects. More information is available at www.applieddata.org .

About Applied Data Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Contact:

Greg Stone Voice: 603-595-6225 Fax: 603-804-0466 www.applieddata.org

Source: Applied Data Research


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->